Oncolytics Ev To Sales vs Price To Sales Ratio Analysis
ONC Stock | CAD 1.26 0.01 0.79% |
Oncolytics Biotech financial indicator trend analysis is much more than just breaking down Oncolytics Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oncolytics Biotech is a good investment. Please check the relationship between Oncolytics Biotech Ev To Sales and its Price To Sales Ratio accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.
Ev To Sales vs Price To Sales Ratio
Ev To Sales vs Price To Sales Ratio Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oncolytics Biotech Ev To Sales account and Price To Sales Ratio. At this time, the significance of the direction appears to have totally related.
The correlation between Oncolytics Biotech's Ev To Sales and Price To Sales Ratio is 1.0. Overlapping area represents the amount of variation of Ev To Sales that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Oncolytics Biotech, assuming nothing else is changed. The correlation between historical values of Oncolytics Biotech's Ev To Sales and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Sales of Oncolytics Biotech are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Ev To Sales i.e., Oncolytics Biotech's Ev To Sales and Price To Sales Ratio go up and down completely randomly.
Correlation Coefficient | 1.0 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Price To Sales Ratio
Price to Sales Ratio is figured by comparing Oncolytics Biotech stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Oncolytics Biotech sales, a figure that is much harder to manipulate than other Oncolytics Biotech multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Most indicators from Oncolytics Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oncolytics Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.At this time, Oncolytics Biotech's Selling General Administrative is very stable compared to the past year. As of the 4th of December 2024, Enterprise Value is likely to grow to about 118 M, while Tax Provision is likely to drop about 82.9 K.
2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 98.6K | 528K | 1.3M | 1.4M | Interest Income | 19.9K | 528K | 1.3M | 1.8M |
Oncolytics Biotech fundamental ratios Correlations
Click cells to compare fundamentals
Oncolytics Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Oncolytics Biotech fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 19.7M | 34.3M | 45.9M | 37.3M | 38.8M | 30.5M | |
Total Current Liabilities | 12.9M | 2.7M | 2.7M | 3.9M | 4.2M | 3.9M | |
Total Stockholder Equity | (107.9K) | 24.8M | 36.1M | 26.5M | 27.6M | 17.8M | |
Property Plant And Equipment Net | 727.5K | 609.1K | 976.3K | 652K | 647K | 460.6K | |
Net Debt | (13.6M) | (30.8M) | (40.6M) | (11.3M) | (34.5M) | (32.8M) | |
Retained Earnings | (344.6M) | (367.1M) | (393.4M) | (418.3M) | (446.0M) | (423.7M) | |
Accounts Payable | 3.2M | 1.8K | 594K | 2.3M | 1.1M | 1.0M | |
Cash | 14.1M | 31.2M | 41.3M | 11.7M | 34.9M | 19.4M | |
Non Current Assets Total | 727.5K | 609.1K | 976.3K | 1.7M | 647K | 614.7K | |
Cash And Short Term Investments | 14.1M | 31.2M | 41.3M | 32.1M | 34.9M | 26.6M | |
Net Receivables | 2.1M | 89.7K | 866.1K | 521K | 15K | 14.3K | |
Common Stock Shares Outstanding | 22.1M | 40.3M | 53.5M | 58.0M | 67.6M | 71.0M | |
Liabilities And Stockholders Equity | 19.7M | 34.3M | 45.9M | 37.3M | 38.8M | 30.5M | |
Non Current Liabilities Total | 6.9M | 6.9M | 7.1M | 6.9M | 7.0M | 7.4M | |
Other Current Assets | 1.5M | 2.4M | 2.8M | 3.0M | 3.2M | 3.4M | |
Other Stockholder Equity | 33.0M | 31.0M | 34.2M | 40.1M | 42.1M | 42.9M | |
Total Liab | 19.8M | 9.6M | 9.8M | 10.8M | 11.3M | 6.0M | |
Property Plant And Equipment Gross | 727.5K | 609.1K | 976.3K | 652K | 1.3M | 1.4M | |
Total Current Assets | 18.9M | 33.7M | 44.9M | 35.7M | 38.2M | 28.0M | |
Accumulated Other Comprehensive Income | 464.1K | 400.2K | 387.7K | 662K | 544K | 516.8K | |
Short Term Investments | 13.1M | 30.4M | 1.4M | 20.5M | 3.4M | 3.2M | |
Short Term Debt | 339.8K | 248.9K | 294K | 216K | 133K | 126.4K | |
Other Current Liab | 12.5M | 2.5M | 1.8M | 1.5M | 3.0M | 3.2M | |
Common Stock | 311.1M | 356.8M | 391.3M | 404.0M | 430.9M | 310.7M | |
Common Stock Total Equity | 271.7M | 285.2M | 311.1M | 356.8M | 410.3M | 294.9M | |
Net Tangible Assets | (107.9K) | 24.8M | 36.1M | 26.5M | 30.5M | 19.0M | |
Property Plant Equipment | 727.5K | 609.1K | 976.3K | 652K | 749.8K | 610.4K | |
Capital Surpluse | 33.0M | 34.6M | 37.8M | 40.1M | 46.1M | 35.9M | |
Long Term Debt Total | 166.4K | 153.2K | 361.1K | 157K | 180.6K | 131.6K | |
Cash And Equivalents | 1.1M | 858.0K | 1.4M | 11.7M | 13.4M | 14.1M | |
Current Deferred Revenue | (3.2K) | (1.8K) | (594K) | (1.1M) | (973.8K) | (925.1K) | |
Net Invested Capital | (107.9K) | 24.8M | 36.1M | 26.5M | 27.6M | 20.3M | |
Net Working Capital | 6.1M | 31.0M | 42.2M | 31.7M | 33.9M | 26.6M | |
Capital Stock | 311.1M | 356.8M | 391.3M | 404.0M | 430.9M | 399.6M |
Pair Trading with Oncolytics Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncolytics Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Oncolytics Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncolytics Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncolytics Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncolytics Biotech to buy it.
The correlation of Oncolytics Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncolytics Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncolytics Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oncolytics Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.